-
AI-driven Alternative Medicine: A Novel Approach to Drug Discovery and Repurposing
Authors:
Oleksandr Bilokon,
Nataliya Bilokon,
Paul Bilokon
Abstract:
AIAltMed is a cutting-edge platform designed for drug discovery and repurposing. It utilizes Tanimoto similarity to identify structurally similar non-medicinal compounds to known medicinal ones. This preprint introduces AIAltMed, discusses the concept of `AI-driven alternative medicine,' evaluates Tanimoto similarity's advantages and limitations, and details the system's architecture. Furthermore,…
▽ More
AIAltMed is a cutting-edge platform designed for drug discovery and repurposing. It utilizes Tanimoto similarity to identify structurally similar non-medicinal compounds to known medicinal ones. This preprint introduces AIAltMed, discusses the concept of `AI-driven alternative medicine,' evaluates Tanimoto similarity's advantages and limitations, and details the system's architecture. Furthermore, it explores the benefits of extending the system to include PubChem and outlines a corresponding implementation strategy.
△ Less
Submitted 2 July, 2024;
originally announced July 2024.
-
Evolution-Bootstrapped Simulation: Artificial or Human Intelligence: Which Came First?
Authors:
Paul Alexander Bilokon
Abstract:
Humans have created artificial intelligence (AI), not the other way around. This statement is deceptively obvious. In this note, we decided to challenge this statement as a small, lighthearted Gedankenexperiment. We ask a simple question: in a world driven by evolution by natural selection, would neural networks or humans be likely to evolve first? We compare the Solomonoff--Kolmogorov--Chaitin co…
▽ More
Humans have created artificial intelligence (AI), not the other way around. This statement is deceptively obvious. In this note, we decided to challenge this statement as a small, lighthearted Gedankenexperiment. We ask a simple question: in a world driven by evolution by natural selection, would neural networks or humans be likely to evolve first? We compare the Solomonoff--Kolmogorov--Chaitin complexity of the two and find neural networks (even LLMs) to be significantly simpler than humans. Further, we claim that it is unnecessary for any complex human-made equipment to exist for there to be neural networks. Neural networks may have evolved as naturally occurring objects before humans did as a form of chemical reaction-based or enzyme-based computation. Now that we know that neural networks can pass the Turing test and suspect that they may be capable of superintelligence, we ask whether the natural evolution of neural networks could lead from pure evolution by natural selection to what we call evolution-bootstrapped simulation. The evolution of neural networks does not involve irreducible complexity; would easily allow irreducible complexity to exist in the evolution-bootstrapped simulation; is a falsifiable scientific hypothesis; and is independent of / orthogonal to the issue of intelligent design.
△ Less
Submitted 6 January, 2024;
originally announced February 2024.
-
A compendium of data sources for data science, machine learning, and artificial intelligence
Authors:
Paul Bilokon,
Oleksandr Bilokon,
Saeed Amen
Abstract:
Recent advances in data science, machine learning, and artificial intelligence, such as the emergence of large language models, are leading to an increasing demand for data that can be processed by such models. While data sources are application-specific, and it is impossible to produce an exhaustive list of such data sources, it seems that a comprehensive, rather than complete, list would still b…
▽ More
Recent advances in data science, machine learning, and artificial intelligence, such as the emergence of large language models, are leading to an increasing demand for data that can be processed by such models. While data sources are application-specific, and it is impossible to produce an exhaustive list of such data sources, it seems that a comprehensive, rather than complete, list would still benefit data scientists and machine learning experts of all levels of seniority. The goal of this publication is to provide just such an (inevitably incomplete) list -- or compendium -- of data sources across multiple areas of applications, including finance and economics, legal (laws and regulations), life sciences (medicine and drug discovery), news sentiment and social media, retail and ecommerce, satellite imagery, and shipping and logistics, and sports.
△ Less
Submitted 10 September, 2023;
originally announced September 2023.
-
An in silico drug repurposing pipeline to identify drugs with the potential to inhibit SARS-CoV-2 replication
Authors:
Méabh MacMahon,
Woochang Hwang,
Soorin Yim,
Eoghan MacMahon,
Alexandre Abraham,
Justin Barton,
Mukunthan Tharmakulasingam,
Paul Bilokon,
Vasanthi Priyadarshini Gaddi,
Namshik Han
Abstract:
Drug repurposing provides an opportunity to redeploy drugs, which ideally are already approved for use in humans, for the treatment of other diseases. For example, the repurposing of dexamethasone and baricitinib has played a crucial role in saving patient lives during the ongoing SARS-CoV-2 pandemic. There remains a need to expand therapeutic approaches to prevent life-threatening complications i…
▽ More
Drug repurposing provides an opportunity to redeploy drugs, which ideally are already approved for use in humans, for the treatment of other diseases. For example, the repurposing of dexamethasone and baricitinib has played a crucial role in saving patient lives during the ongoing SARS-CoV-2 pandemic. There remains a need to expand therapeutic approaches to prevent life-threatening complications in patients with COVID-19. Using an in silico approach based on structural similarity to drugs already in clinical trials for COVID-19, potential drugs were predicted for repurposing. For a subset of identified drugs with different targets to their corresponding COVID-19 clinical trial drug, a mechanism of action analysis was applied to establish whether they might have a role in inhibiting the replication of SARS-CoV-2. Of sixty drugs predicted in this study, two with the potential to inhibit SARS-CoV-2 replication were identified using mechanism of action analysis. Triamcinolone is a corticosteroid that is structurally similar to dexamethasone; gallopamil is a calcium channel blocker that is structurally similar to verapamil. In silico approaches indicate possible mechanisms of action for both drugs in inhibiting SARS-CoV-2 replication. The identification of these drugs as potentially useful for patients with COVID-19 who are at a higher risk of developing severe disease supports the use of in silico approaches to facilitate quick and cost-effective drug repurposing. Such drugs could expand the number of treatments available to patients who are not protected by vaccination.
△ Less
Submitted 23 November, 2022; v1 submitted 5 July, 2021;
originally announced July 2021.
